Table 1.
Demographic breakdown of the participants by time period of infection.
| Infected during BA.1/2 wave (n = 122) | Infected during BA.4/5 wave (n = 49) | Overall (n = 171) | P-value | |
|---|---|---|---|---|
| Age (years), mean ± SD (range) | 39.3 ± 10.7 (22–68) | 41.8 ± 11.0 (23–66) | 40.0 ± 10.8 (22–68) | 0.18a |
| Sex, n (%) | 0.09b | |||
| Female | 108 (88.5%) | 38 (77.6%) | 146 (85.4%) | |
| Male | 14 (11.5%) | 11 (22.4%) | 25 (14.6%) | |
| Race, n (%) | ||||
| Asian | 9 (7.4%) | 3 (6.1%) | 12 (7.0%) | |
| Black or African American | 11 (9.0%) | 2 (4.1%) | 13 (7.6%) | |
| White | 89 (72.9%) | 44 (89.8%) | 133 (77.8%) | |
| Native Hawaiian or Pacific Islander | 1 (0.8%) | 0 (0%) | 1 (0.6%) | |
| Other | 8 (6.6%) | 0 (0%) | 8 (4.7%) | |
| Unknown | 4 (3.3%) | 0 (0%) | 4 (2.3%) | |
| Vaccine brand, n (%) | ||||
| Pfizer | 120 (98.4%) | 49 (100%) | 169 (98.8%) | |
| Moderna | 2 (1.6%) | 0 (0%) | 2 (1.2%) |
SD, standard deviation.
a
t-test with Welch correction: P = 0.18 comparing age between the BA.1/2 and BA.4/5 waves.
b
Fisher's exact test: P = 0.09 comparing the sex ratio between the BA.1/2 and BA.4/5 waves.